§ BIOTECHNOLOGY
USD · Biotechnology

AUTL

AUTOLUS THERAPEUTICS PLC
USDSector · Biotechnology
LAST
n/a
n/aPREV CLOSE · n/a
§ 01 · PRICE
Price action
1D5D1M6MYTD1YMAX

§ 03 · SIGNAL STACK · WHAT THE INPUTS SAY

13F FLOW
39 increased/new, 22 decreased/exited (13F)
AC 13F Analysis
§ 05 · WHO OWNS IT
Top institutional holders
All holders →
FundShares% portΔ Q/Q
MAK CAPITAL ONE LLC33.6M6.8%+12%
Syncona Portfolio Ltd16.6M89.3%±0%
ARMISTICE CAPITAL, LLC15.8M0.4%−10%
Tetragon Partners GP Ltd9.5M2.5%±0%
SCHRODER INVESTMENT MANAGEMENT GROUP9.5M0.0%±0%
Frazier Life Sciences Management, L.P.4.4M0.2%−4%
AC INTELLIGENCE

Top institutional owners for AUTL as of the most recent 13F reporting period (Q1 2026 · Period ended Mar 31). Δ Q/Q reflects share-count change vs. the prior filing — positive green means adding, negative red means trimming. Cross-reference with the ownership-mix bars below to see which strategy cohort is driving the flow.

§ 06 · WHO OWNS IT · BY STRATEGY

OTHER49.3% · 0 holders
OTHER42.8% · 60 holders
QUALITY / COMPOUNDER3.6% · 1 holder
DEALER / BANK2.0% · 11 holders
SYSTEMATIC / QUANT0.9% · 3 holders
TACTICAL / MACRO0.7% · 4 holders
PASSIVE / INDEX0.6% · 5 holders
INCOME / DEFENSIVE0.0% · 1 holder
AC INTELLIGENCE

Ownership mix by behavioral cohort. Top bars indicate which style of capital dominates the float — passive indexing, quality compounders, dealer/bank, systematic quant, etc. Big quality-compounder share means concentrated active conviction; heavy passive share means flows are dictated by index rebalances, not fundamentals.

§ 07 · INSIDER ACTIVITY · LAST 180 DAYS

NO INSIDER FILINGS
AC INTELLIGENCE

No Form 4 filings on record for AUTL in the last 180 days.

§ 08 · COVERAGE · OUR RECENT NOTES

No notes mention AUTL yet.